Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
In order to succeed in today’s B2B sales world, salespeople must create buyer consensus among diverse customer stakeholders. Those who fail to do that risk falling victim to the status-quo – the minimal-risk, lowest-cost option – or worse, losing the deal altogether. The Challenger Customer: Selling to the Hidden Influencer Who Can Multiply Your Results from CEB (NYSE: CEB), a best practice insight and technology company, reveals that it isn’t just about how you engage, but who you engage within the customer organization that drives complex sales today.
“The ‘senior decision-maker’ no longer exists in B2B sales. That makes the most significant problem facing marketing and sales teams a buying problem, not a selling problem. Organizations need to shift their focus from making the sale to understanding buyer groups – and who among them really shapes decisions,” said co-author Brent Adamson, executive advisor at CEB. “Our research shows that the one thing that matters most to executives is whether or not a supplier has buy-in with the rest of the organization – NOT the supplier’s actual offering or solution.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7427252-ceb-the-challenger-customer/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Subaru of America, Inc. today announced the completion of a Pet Travel Seat Pilot Study as part of its continued partnership with Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization. Subaru and CPS have tested pet products most commonly used by pet parents when traveling. Phase one tested pet harnesses, phase two tested pet crates and carriers, and now, phase three has tested pet travel seats.
A pet travel seat is typically used in a vehicle to hold or elevate the pet, but does not offer full containment. The Pet Travel Seat Pilot Study found that while a pet travel seat may offer distraction prevention, it will likely not offer crash protection in the event of an accident, which could lead to injury of the pet and the human vehicle passengers. The quality of commonly available pet travel seats did not provide effective protection in a crash scenario.
Based on the scientific test evidence collected over the past four years, in part through its partnership with Subaru, CPS can now identify the safest travel options for most pets. For small dogs and cats, Center for Pet Safety recommends one of the 2015 Top Performing Carriers; for medium and large dogs either the 2015 Top Performing Crate - Gunner Kennels G1 Intermediate with 8' Tie Down Straps, or a Center for Pet Safety Certified Harness. To view top performing products and CPS Certified products, visit www.CenterforPetSafety.org.
To view the multimedia release go to:
http://www.multivu.com/players/English/7074158-subaru-cps-pet-travel-seat-study/
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Positive strides have been made since 1995 to advance science literacy in the United States, but teachers and parents agree that more hands-on, experiential learning must be adopted in order to improve science education for future generations, according to the results of the 2015 Bayer Facts of Science Education Survey released today.
For 20 years, Bayer has issued the survey, which assesses science education in the United States and evaluates its development. Although positive strides have been made, survey results emphasize the critical need to improve science education and literacy for future generations. Teachers, for example, universally agree (99 percent) that more hands-on experiential learning in general would benefit student learning.
In response, Bayer is announcing a five-year commitment to provide 1 million hands-on science learning experiences for children by 2020, timed to the 20th anniversary of the Making Science Make Sense® program, Bayer’s company-wide initiative that advances science literacy across the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7452954-bayer-children-science-education/
T. Rowe Price’s 2015 Parents, Kids & Money Survey revealed that having conversations with kids about money is critical to raising financially savvy kids. There is also a significant benefit in letting kids experience money, and providing an allowance is one way to do that. Parents who combine conversations with experiential learning are most likely to have financially smart kids.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7455231-t-rowe-price-financial-education/
The aluminum-body 2015 Ford F-150 crew cab swept the Insurance Institute for Highway Safety’s full slate of crashworthiness evaluations to qualify for a 2015 TOP SAFETY PICK award. The F-150 extended cab turned in a good performance in 4 of 5 assessments but stumbled in the small overlap front test. The results are the first ratings for large pickups in a group the Institute is evaluating this year.
The F-150 crew cab, which Ford calls the SuperCrew, earns good ratings for occupant protection in all five IIHS crashworthiness evaluations — small overlap front, moderate overlap front, side, roof strength and head restraint evaluations. The extended cab, or SuperCab, earns good ratings in the moderate overlap front, side, roof strength and head restraint evaluations but just a marginal rating for occupant protection in a small overlap front crash.
Subaru of America, Inc. and Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization, announced today the results of the 2015 Crate and Carrier Crashworthiness Studies - a collaborative initiative to examine the effectiveness and safety of pet crates and carriers in the event of a crash. After several eye-opening and informative tests - including instances of complete failure - three top products emerged; CPS has selected the Gunner Kennels G1 Intermediate with 8’ Tie Down Straps as the 2015 Top Performing Crate and both the PetEgo Forma Frame Jet Set Carrier with ISOFIX-Latch Connection and Sleepypod Mobile Pet Bed with PPRS Handilock as the 2015 Top Performing Carriers.
To view the multimedia news release, go to http://www.multivu.com/players/English/7074157-subaru-pet-safety/
Summer is here, and TruGreen is releasing results to a national survey that reveals a few of America’s favorite outdoor pastimes as well as tips for creating easy activities for the whole neighborhood. In a short video, TruGreen Spokesperson Jason Cameron provides suggestions for how Americans can create fun yard games and “gamify” their lawn this summer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7549551-trugreen-livelifeoutside-backyard-ideas/
